[Tadalafil Ameliorates Symptoms of Patients with Benign Prostatic Hyperplasia Complicated by Chronic Pelvic Pain Syndrome].
To examine the efficacy and safety of tadalafil in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia with chronic pelvic pain syndrome, we treated 23 Japanese men with tadalafil 5 mg once daily for 4 weeks. The mean age of the participantswas58.7 yearsand the prostate volume was25. 2 ml. Significant improvementsin total International Prostatic Symptom Score, International Prostatic Symptom Score Quality of Life Index, total National Institutes of Health Chronic Prostatitis Symptom Index score, pain subscore, urinary symptom subscore, and quality of life impact subscore, were observed for tadalafil versus before treatment. These findings confirm that tadalafil is a valuable new treatment option for patients with benign prostatic hyperplasia complicated by chronic pelvic pain syndrome.
Nishino Clinic.
Yoshinori
Y
Nishino
The Department of Urology, Japanese Red Cross Gifu Hospital.
Kousei
K
Miwa
The Department of Urology, Japanese Red Cross Gifu Hospital.
Yoji
Y
Moriyama
The Department of Urology, Japanese Red Cross Gifu Hospital.
Shigeru
S
Fujihiro
The Department of Urology, Ogaki Municipal Hospital.
Takako
T
Masue
The Department of Urology, Tokai Central Hospital.
Mina
M
Kikuchi
The Department of Urology, Division of Disease Control, Research Field of Medical Sciences, Graduate School of Medicine, Gifu University.
Chie
C
Nakai
The Department of Urology, Division of Disease Control, Research Field of Medical Sciences, Graduate School of Medicine, Gifu University.
Takashi
T
Deguchi
D006801:Humans; D008297:Male; D008875:Middle Aged; D017699:Pelvic Pain / Q000209:etiology*; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D000068581:Tadalafil / Q000627:therapeutic use*; D016896:Treatment Outcome
D058986:Phosphodiesterase 5 Inhibitors; D000068581:Tadalafil